{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:24:04Z","timestamp":1791685444282,"version":"4.3.4"},"reference-count":115,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1248\/bpb.b17-00856","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T22:22:52Z","timestamp":1530397372000},"page":"1006-1013","source":"Crossref","is-referenced-by-count":10,"title":["Physiological Roles of Metallothioneins in Central Nervous System Diseases"],"prefix":"10.1248","volume":"41","author":[{"given":"Shinsuke","family":"Nakamura","sequence":"first","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Shimazawa","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hara","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Hidalgo J, Aschner M, Zatta P, Vasak M. Roles of the metallothionein family of proteins in the central nervous system. Brain Res. Bull.<\/i>, 55<\/b>, 133\u2013145 (2001).","DOI":"10.1016\/S0361-9230(01)00452-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Piotrowski JK, Trojanowska B, Sapota A. Binding of cadmium and mercury by metallothionein in the kidneys and liver of rats following repeated administration. Arch. Toxicol.<\/i>, 32<\/b>, 351\u2013360 (1974).","DOI":"10.1007\/BF00330118"},{"key":"3","unstructured":"3) Hildebrand CE, Griffith JK, Tobey RA, Walters RA, Enger MD. Molecular mechanisms of cadmium detoxification in cadmium-resistant cultured cells: role of metallothionein and other inducible factors. Dev. Toxicol. Environ. Sci.<\/i>, 9<\/b>, 279\u2013303 (1982)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Richards MP. Recent developments in trace element metabolism and function: role of metallothionein in copper and zinc metabolism. J. Nutr.<\/i>, 119<\/b>, 1062\u20131070 (1989).","DOI":"10.1093\/jn\/119.7.1062"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wang H, Zhang Q, Cai B, Li H, Sze KH, Huang ZX, Wu HM, Sun H. Solution structure and dynamics of human metallothionein-3 (MT-3). FEBS Lett.<\/i>, 580<\/b>, 795\u2013800 (2006).","DOI":"10.1016\/j.febslet.2005.12.099"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Hozumi I, Suzuki JS, Kanazawa H, Hara A, Saio M, Inuzuka T, Miyairi S, Naganuma A, Tohyama C. Metallothionein-3 is expressed in the brain and various peripheral organs of the rat. Neurosci. Lett.<\/i>, 438<\/b>, 54\u201358 (2008).","DOI":"10.1016\/j.neulet.2008.04.047"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Meloni G, Zovo K, Kazantseva J, Palumaa P, Vasak M. Organization and assembly of metal-thiolate clusters in epithelium-specific metallothionein-4. J. Biol. Chem.<\/i>, 281<\/b>, 14588\u201314595 (2006).","DOI":"10.1074\/jbc.M601724200"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ugarte M, Osborne NN. Recent advances in the understanding of the role of zinc in ocular tissues. Metallomics<\/i>, 6<\/b>, 189\u2013200 (2014).","DOI":"10.1039\/C3MT00291H"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Xu J, Zhou Q, Liu G, Tan Y, Cai L. Analysis of serum and urinal copper and zinc in Chinese northeast population with the prediabetes or diabetes with and without complications. Oxid. Med. Cell. Longev.<\/i>, 2013<\/b>, 635214 (2013).","DOI":"10.1155\/2013\/635214"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) DeToma AS, Dengler-Crish CM, Deb A, Braymer JJ, Penner-Hahn JE, van der Schyf CJ, Lim MH, Crish SD. Abnormal metal levels in the primary visual pathway of the DBA\/2J mouse model of glaucoma. Biometals<\/i>, 27<\/b>, 1291\u20131301 (2014).","DOI":"10.1007\/s10534-014-9790-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yang G, Chan PH, Chen J, Carlson E, Chen SF, Weinstein P, Epstein CJ, Kamii H. Human copper\u2013zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke<\/i>, 25<\/b>, 165\u2013170 (1994).","DOI":"10.1161\/01.STR.25.1.165"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Vidovic B, Dordevic B, Milovanovic S, Skrivanj S, Pavlovic Z, Stefanovic A, Kotur-Stevuljevic J. Selenium, zinc, and copper plasma levels in patients with schizophrenia: relationship with metabolic risk factors. Biol. Trace Elem. Res.<\/i>, 156<\/b>, 22\u201328 (2013).","DOI":"10.1007\/s12011-013-9842-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Li Z, Li B, Song X, Zhang D. Dietary zinc and iron intake and risk of depression: A meta-analysis. Psychiatry Res.<\/i>, 251<\/b>, 41\u201347 (2017).","DOI":"10.1016\/j.psychres.2017.02.006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ahmad S, Wang Y, Shaik GM, Burghes AH, Gangwani L. The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy. Hum. Mol. Genet.<\/i>, 21<\/b>, 2745\u20132758 (2012).","DOI":"10.1093\/hmg\/dds102"},{"key":"15","unstructured":"15) Hosler BA, Brown RH Jr. Copper\/zinc superoxide dismutase mutations and free radical damage in amyotrophic lateral sclerosis. Adv. Neurol.<\/i>, 68<\/b>, 41\u201346 (1995)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nishikawa M, Mori H, Hara M. Reduced zinc cytotoxicity following differentiation of neural stem\/progenitor cells into neurons and glial cells is associated with upregulation of metallothioneins. Environ. Toxicol. Pharmacol.<\/i>, 39<\/b>, 1170\u20131176 (2015).","DOI":"10.1016\/j.etap.2015.04.009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Conway DE, Lee S, Eskin SG, Shah AK, Jo H, McIntire LV. Endothelial metallothionein expression and intracellular free zinc levels are regulated by shear stress. Am. J. Physiol. Cell Physiol.<\/i>, 299<\/b>, C1461\u2013C1467 (2010).","DOI":"10.1152\/ajpcell.00570.2009"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Asakuno K, Isono M, Wakabayashi Y, Mori T, Hori S, Kohno K, Kuwano M. The exogenous control of transfected c-fos gene expression and angiogenesis in cells implanted into the rat brain. Brain Res.<\/i>, 702<\/b>, 23\u201331 (1995).","DOI":"10.1016\/0006-8993(95)00880-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Morahan G, Brennan FE, Bhathal PS, Allison J, Cox KO, Miller JF. Expression in transgenic mice of class I histocompatibility antigens controlled by the metallothionein promoter. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 86<\/b>, 3782\u20133786 (1989).","DOI":"10.1073\/pnas.86.10.3782"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Giralt M, Penkowa M, Lago N, Molinero A, Hidalgo J. Metallothionein-1+2 protect the CNS after a focal brain injury. Exp. Neurol.<\/i>, 173<\/b>, 114\u2013128 (2002).","DOI":"10.1006\/exnr.2001.7772"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Murakami S, Miyazaki I, Sogawa N, Miyoshi K, Asanuma M. Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice. Neurotox. Res.<\/i>, 26<\/b>, 285\u2013298 (2014).","DOI":"10.1007\/s12640-014-9480-1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Palmiter RD, Findley SD, Whitmore TE, Durnam DM. MT-III, a brain-specific member of the metallothionein gene family. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 89<\/b>, 6333\u20136337 (1992).","DOI":"10.1073\/pnas.89.14.6333"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA<\/i>, 291<\/b>, 1900\u20131901 (2004).","DOI":"10.1001\/jama.291.15.1900"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology<\/i>, 102<\/b>, 1450\u20131460 (1995).","DOI":"10.1016\/S0161-6420(95)30846-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology<\/i>, 99<\/b>, 933\u2013943 (1992).","DOI":"10.1016\/S0161-6420(92)31871-8"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Bauer P, Barthelmes D, Kurz M, Fleischhauer JC, Sutter FK. The potential effect of population development, smoking and antioxidant supplementation on the future epidemiology of age-related macular degeneration in switzerland. Klin. Monatsbl. Augenheilkd.<\/i>, 225<\/b>, 376\u2013379 (2008).","DOI":"10.1055\/s-2008-1027264"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Friedman DS, O\u2019Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol.<\/i>, 122<\/b>, 564\u2013572 (2004).","DOI":"10.1001\/archopht.122.4.564"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br. J. Ophthalmol.<\/i>, 96<\/b>, 752\u2013756 (2012).","DOI":"10.1136\/bjophthalmol-2011-301109"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Baird PN, Richardson AJ, Robman LD, Dimitrov PN, Tikellis G, McCarty CA, Guymer RH. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum. Mutat.<\/i>, 27<\/b>, 337\u2013342 (2006).","DOI":"10.1002\/humu.20288"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. Science<\/i>, 308<\/b>, 419\u2013421 (2005).","DOI":"10.1126\/science.1110359"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kanda A, Chen W, Othman M, Branham KE, Brooks M, Khanna R, He S, Lyons R, Abecasis GR, Swaroop A. A variant of mitochondrial protein LOC387715\/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 104<\/b>, 16227\u201316232 (2007).","DOI":"10.1073\/pnas.0703933104"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA<\/i>, 276<\/b>, 1147\u20131151 (1996).","DOI":"10.1001\/jama.1996.03540140035023"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA<\/i>, 276<\/b>, 1141\u20131146 (1996).","DOI":"10.1001\/jama.1996.03540140029022"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch\u2019s membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res.<\/i>, 20<\/b>, 705\u2013732 (2001).","DOI":"10.1016\/S1350-9462(01)00010-6"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Mohamed R, Sharma I, Ibrahim AS, Saleh H, Elsherbiny NM, Fulzele S, Elmasry K, Smith SB, Al-Shabrawey M, Tawfik A. Hyperhomocysteinemia alters retinal endothelial cells barrier function and angiogenic potential via<\/i> activation of oxidative stress. Scientific Reports<\/i>, 7<\/b>, 11952 (2017).","DOI":"10.1038\/s41598-017-09731-y"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Semkova I, Kociok N, Karagiannis D, Nischt R, Smyth N, Paulsson M, Strauss O, Joussen AM. Anti-angiogenic effect of the basement membrane protein nidogen-1 in a mouse model of choroidal neovascularization. Exp. Eye Res.<\/i>, 118<\/b>, 80\u201388 (2014).","DOI":"10.1016\/j.exer.2013.11.006"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Jampol LM, Ferris FL 3rd. Antioxidants and zinc to prevent progression of age-related macular degeneration. JAMA<\/i>, 286<\/b>, 2466\u20132468 (2001).","DOI":"10.1001\/jama.286.19.2466"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Yoshinaga N, Arimura N, Otsuka H, Kawahara K, Hashiguchi T, Maruyama I, Sakamoto T. NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway. Lab. Invest.<\/i>, 91<\/b>, 1277\u20131290 (2011).","DOI":"10.1038\/labinvest.2011.101"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Ivanescu AA, Fernandez-Robredo P, Heras-Mulero H, Sadaba-Echarri LM, Garcia-Garcia L, Fernandez-Garcia V, Moreno-Orduna M, Redondo-Exposito A, Recalde S, Garcia-Layana A. Modifying choroidal neovascularization development with a nutritional supplement in mice. Nutrients<\/i>, 7<\/b>, 5423\u20135442 (2015).","DOI":"10.3390\/nu7075229"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Masuda T, Shimazawa M, Takata S, Nakamura S, Tsuruma K, Hara H. Edaravone is a free radical scavenger that protects against laser-induced choroidal neovascularization in mice and common marmosets. Exp. Eye Res.<\/i>, 146<\/b>, 196\u2013205 (2016).","DOI":"10.1016\/j.exer.2016.03.020"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Tang ZL, Wasserloos KJ, Liu X, Stitt MS, Reynolds IJ, Pitt BR, St Croix CM. Nitric oxide decreases the sensitivity of pulmonary endothelial cells to LPS-induced apoptosis in a zinc-dependent fashion. Mol. Cell. Biochem.<\/i>, 234\u2013235<\/b>, 211\u2013217 (2002).","DOI":"10.1023\/A:1015930927407"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Nakamura S, Shimazawa M, Inoue Y, Takata S, Ito Y, Tsuruma K, Ikeda T, Honda A, Satoh M, Hara H. Role of metallothioneins 1 and 2 in ocular neovascularization. Invest. Ophthalmol. Vis. Sci.<\/i>, 55<\/b>, 6851\u20136860 (2014).","DOI":"10.1167\/iovs.14-14545"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Choi JA, Hwang JU, Yoon YH, Koh JY. Methallothionein-3 contributes to vascular endothelial growth factor induction in a mouse model of choroidal neovascularization. Metallomics<\/i>, 5<\/b>, 1387\u20131396 (2013).","DOI":"10.1039\/c3mt00150d"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Tsuruma K, Shimazaki H, Ohno Y, Inoue Y, Honda A, Imai S, Lee J, Shimazawa M, Satoh M, Hara H. Metallothionein-III deficiency exacerbates light-induced retinal degeneration. Invest. Ophthalmol. Vis. Sci.<\/i>, 53<\/b>, 7896\u20137903 (2012).","DOI":"10.1167\/iovs.12-10165"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N. Engl. J. Med.<\/i>, 366<\/b>, 1227\u20131239 (2012).","DOI":"10.1056\/NEJMra1005073"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet<\/i>, 376<\/b>, 124\u2013136 (2010).","DOI":"10.1016\/S0140-6736(09)62124-3"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Klein R, Klein BE. Are individuals with diabetes seeing better?: a long-term epidemiological perspective. Diabetes<\/i>, 59<\/b>, 1853\u20131860 (2010).","DOI":"10.2337\/db09-1904"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: A meta-analysis from 1990 to 2010. Diabetes Care<\/i>, 39<\/b>, 1643\u20131649 (2016).","DOI":"10.2337\/dc15-2171"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Cunha-Vaz J. Characterization and relevance of different diabetic retinopathy phenotypes. Dev. Ophthalmol.<\/i>, 39<\/b>, 13\u201330 (2007).","DOI":"10.1159\/000098497"},{"key":"50","unstructured":"50) Zhang C, Wang H, Nie J, Wang F. Protective factors in diabetic retinopathy: focus on blood-retinal barrier. Discov. Med.<\/i>, 18<\/b>, 105\u2013112 (2014)."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol.<\/i>, 142<\/b>, 961\u2013969 (2006).","DOI":"10.1016\/j.ajo.2006.06.068"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Suzuma K, Takagi H, Otani A, Suzuma I, Honda Y. Increased expression of KDR\/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization. Microvasc. Res.<\/i>, 56<\/b>, 183\u2013191 (1998).","DOI":"10.1006\/mvre.1998.2111"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Penkowa M, Carrasco J, Giralt M, Molinero A, Hernandez J, Campbell IL, Hidalgo J. Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. J. Cereb. Blood Flow Metab.<\/i>, 20<\/b>, 1174\u20131189 (2000).","DOI":"10.1097\/00004647-200008000-00003"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Wang Y, Feng W, Xue W, Tan Y, Hein DW, Li XK, Cai L. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes<\/i>, 58<\/b>, 1391\u20131402 (2009).","DOI":"10.2337\/db08-1697"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Li X, Chen H, Epstein PN. Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J. Biol. Chem.<\/i>, 279<\/b>, 765\u2013771 (2004).","DOI":"10.1074\/jbc.M307907200"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol.<\/i>, 90<\/b>, 262\u2013267 (2006).","DOI":"10.1136\/bjo.2005.081224"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog. Retin. Eye Res.<\/i>, 24<\/b>, 39\u201373 (2005).","DOI":"10.1016\/j.preteyeres.2004.06.001"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL, Nishimura D, Clark AF, Nystuen A, Nichols BE, Mackey DA, Ritch R, Kalenak JW, Craven ER, Sheffield VC. Identification of a gene that causes primary open angle glaucoma. Science<\/i>, 275<\/b>, 668\u2013670 (1997).","DOI":"10.1126\/science.275.5300.668"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol.<\/i>, 114<\/b>, 299\u2013305 (1996).","DOI":"10.1001\/archopht.1996.01100130295012"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Aschner M, Cherian MG, Klaassen CD, Palmiter RD, Erickson JC, Bush AI. Metallothioneins in brain\u2014the role in physiology and pathology. Toxicol. Appl. Pharmacol.<\/i>, 142<\/b>, 229\u2013242 (1997).","DOI":"10.1006\/taap.1996.8054"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Hidalgo J, Campmany L, Borras M, Garvey JS, Armario A. Metallothionein response to stress in rats: role in free radical scavenging. Am. J. Physiol.<\/i>, 255<\/b>, E518\u2013E524 (1988).","DOI":"10.1152\/ajpendo.1988.255.4.E518"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Montoliu C, Monfort P, Carrasco J, Palacios O, Capdevila M, Hidalgo J, Felipo V. Metallothionein-III prevents glutamate and nitric oxide neurotoxicity in primary cultures of cerebellar neurons. J. Neurochem.<\/i>, 75<\/b>, 266\u2013273 (2000).","DOI":"10.1046\/j.1471-4159.2000.0750266.x"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Suemori S, Shimazawa M, Kawase K, Satoh M, Nagase H, Yamamoto T, Hara H. Metallothionein, an endogenous antioxidant, protects against retinal neuron damage in mice. Invest. Ophthalmol. Vis. Sci.<\/i>, 47<\/b>, 3975\u20133982 (2006).","DOI":"10.1167\/iovs.06-0275"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Moretti A, Ferrari F, Villa RF. Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol. Ther.<\/i>, 146<\/b>, 23\u201334 (2015).","DOI":"10.1016\/j.pharmthera.2014.09.003"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Eidizadeh A, Khajehalichalehshtari M, Freyer D, Trendelenburg G. Assessment of the therapeutic potential of metallothionein-II application in focal cerebral ischemia in vitro<\/i> and in vivo.<\/i> PLOS ONE<\/i>, 10<\/b>, e0144035 (2015).","DOI":"10.1371\/journal.pone.0144035"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Koumura A, Hamanaka J, Shimazawa M, Honda A, Tsuruma K, Uchida Y, Hozumi I, Satoh M, Inuzuka T, Hara H. Metallothionein-III knockout mice aggravates the neuronal damage after transient focal cerebral ischemia. Brain Res.<\/i>, 1292<\/b>, 148\u2013154 (2009).","DOI":"10.1016\/j.brainres.2009.07.050"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) You HJ, Lee KJ, Jeong HG. Overexpression of human metallothionein-III prevents hydrogen peroxide-induced oxidative stress in human fibroblasts. FEBS Lett.<\/i>, 521<\/b>, 175\u2013179 (2002).","DOI":"10.1016\/S0014-5793(02)02870-3"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Seifuddin F, Pirooznia M, Judy JT, Goes FS, Potash JB, Zandi PP. Systematic review of genome-wide gene expression studies of bipolar disorder. BMC Psychiatry<\/i>, 13<\/b>, 213 (2013).","DOI":"10.1186\/1471-244X-13-213"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Goldman PS, Alexander GE. Maturation of prefrontal cortex in the monkey revealed by local reversible cryogenic depression. Nature<\/i>, 267<\/b>, 613\u2013615 (1977).","DOI":"10.1038\/267613a0"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Berman KF, Weinberger DR. The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: in vivo<\/i> physiological correlates of cognitive deficits. Prog. Brain Res.<\/i>, 85<\/b>, 521\u2013536, discussion, 536\u2013537 (1990).","DOI":"10.1016\/S0079-6123(08)62698-9"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Murphy CM, Christakou A, Giampietro V, Brammer M, Daly EM, Ecker C, Johnston P, Spain D, Robertson DM, Murphy DG, Rubia K. Abnormal functional activation and maturation of ventromedial prefrontal cortex and cerebellum during temporal discounting in autism spectrum disorder. Hum. Brain Mapp.<\/i>, 38<\/b>, 5343\u20135355 (2017).","DOI":"10.1002\/hbm.23718"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Minger SL, Honer WG, Esiri MM, McDonald B, Keene J, Nicoll JA, Carter J, Hope T, Francis PT. Synaptic pathology in prefrontal cortex is present only with severe dementia in Alzheimer disease. J. Neuropathol. Exp. Neurol.<\/i>, 60<\/b>, 929\u2013936 (2001).","DOI":"10.1093\/jnen\/60.10.929"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med.<\/i>, 2<\/b>, 13 (2004).","DOI":"10.1186\/1741-7015-2-13"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br. J. Psychiatry<\/i>, 162<\/b>, 80\u201386 (1993).","DOI":"10.1192\/bjp.162.1.80"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Petronis A. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biological Psychiatry<\/i>, 55<\/b>, 965-970 (2004).","DOI":"10.1016\/j.biopsych.2004.02.005"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch. Gen. Psychiatry<\/i>, 48<\/b>, 239\u2013246 (1991).","DOI":"10.1001\/archpsyc.1991.01810270051007"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Crawford MJ, Killaspy H, Barnes TR, Barrett B, Byford S, Clayton K, Dinsmore J, Floyd S, Hoadley A, Johnson T, Kalaitzaki E, King M, Leurent B, Maratos A, O\u2019Neill FA, Osborn D, Patterson S, Soteriou T, Tyrer P, Waller D. Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE). Health Technol. Assess.<\/i>, 16<\/b>, iii\u2013iv, 1\u201376 (2012).","DOI":"10.3310\/hta16080"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Scarr E, Udawela M, Greenough MA, Neo J, Suk Seo M, Money TT, Upadhyay A, Bush AI, Everall IP, Thomas EA, Dean B. Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. NPJ Schizophrenia<\/i>, 2<\/b>, 16002 (2016).","DOI":"10.1038\/npjschz.2016.2"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Petrilli MA, Kranz TM, Kleinhaus K, Joe P, Getz M, Johnson P, Chao MV, Malaspina D. The emerging role for zinc in depression and psychosis. Frontiers in Pharmacology<\/i>, 8<\/b>, 414 (2017).","DOI":"10.3389\/fphar.2017.00414"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Haase H, Maret W. A differential assay for the reduced and oxidized states of metallothionein and thionein. Anal. Biochem.<\/i>, 333<\/b>, 19\u201326 (2004).","DOI":"10.1016\/j.ab.2004.04.039"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Ruttkay-Nedecky B, Nejdl L, Gumulec J, Zitka O, Masarik M, Eckschlager T, Stiborova M, Adam V, Kizek R. The role of metallothionein in oxidative stress. Int. J. Mol. Sci.<\/i>, 14<\/b>, 6044\u20136066 (2013).","DOI":"10.3390\/ijms14036044"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Heger Z, Rodrigo MA, Krizkova S, Ruttkay-Nedecky B, Zalewska M, Del Pozo EM, Pelfrene A, Pourrut B, Stiborova M, Eckschlager T, Emri G, Kizek R, Adam V. Metallothionein as a scavenger of free radicals-new cardioprotective therapeutic agent or initiator of tumor chemoresistance? Curr. Drug Targets<\/i>, 17<\/b>, 1438\u20131451 (2016).","DOI":"10.2174\/1389450116666151001113304"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Dean B, Gibbons AS, Boer S, Uezato A, Meador-Woodruff J, Scarr E, McCullumsmith RE. Changes in cortical N<\/i>-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide. Aust. N. Z. J. Psychiatry<\/i>, 50<\/b>, 275\u2013283 (2016).","DOI":"10.1177\/0004867415586601"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Zhang W, Wu J, Ward MD, Yang S, Chuang YA, Xiao M, Li R, Leahy DJ, Worley PF. Structural basis of arc binding to synaptic proteins: implications for cognitive disease. Neuron<\/i>, 86<\/b>, 490\u2013500 (2015).","DOI":"10.1016\/j.neuron.2015.03.030"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Peykov S, Berkel S, Schoen M, Weiss K, Degenhardt F, Strohmaier J, Weiss B, Proepper C, Schratt G, Nothen MM, Boeckers TM, Rietschel M, Rappold GA. Identification and functional characterization of rare SHANK2 variants in schizophrenia. Mol. Psychiatry<\/i>, 20<\/b>, 1489\u20131498 (2015).","DOI":"10.1038\/mp.2014.172"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) O\u2019Leary OF, Wu X, Castren E. Chronic fluoxetine treatment increases expression of synaptic proteins in the hippocampus of the ovariectomized rat: role of BDNF signalling. Psychoneuroendocrinology<\/i>, 34<\/b>, 367\u2013381 (2009).","DOI":"10.1016\/j.psyneuen.2008.09.015"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Luoni A, Macchi F, Papp M, Molteni R, Riva MA. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex. Int. J. Neuropsychopharmacol.<\/i>, 18<\/b>, 1\u201312 (2014).","DOI":"10.1093\/ijnp\/pyu061"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J, de Bartolomeis A. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology<\/i>, 212<\/b>, 329\u2013344 (2010).","DOI":"10.1007\/s00213-010-1954-0"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Eramo A, Rossi R, Avvisati L, Latte G, Tomasetti C. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment. Eur. Neuropsychopharmacol.<\/i>, 25<\/b>, 566\u2013582 (2015).","DOI":"10.1016\/j.euroneuro.2015.01.003"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) de Bartolomeis A, Marmo F, Buonaguro EF, Latte G, Tomasetti C, Iasevoli F. Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naive vs.<\/i> antipsychotic-exposed rats. Prog. Neuropsychopharmacol. Biol. Psychiatry<\/i>, 70<\/b>, 24\u201338 (2016).","DOI":"10.1016\/j.pnpbp.2016.04.015"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Feng W, Zhang M. Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density. Nat. Rev. Neurosci.<\/i>, 10<\/b>, 87\u201399 (2009).","DOI":"10.1038\/nrn2540"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Hirabayashi A, Fukunaga Y, Miyazawa A. Structural analysis of the PSD-95 cluster by electron tomography and CEMOVIS: a proposal for the application of the genetically encoded metallothionein tag. Microscopy<\/i> (Oxford, England), 63<\/b>, 227\u2013234 (2014).","DOI":"10.1093\/jmicro\/dfu006"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Tian X, Zheng Y, Li Y, Shen Z, Tao L, Dou X, Qian J, Shen H. Psychological stress induced zinc accumulation and up-regulation of ZIP14 and metallothionein in rat liver. BMC Gastroenterol.<\/i>, 14<\/b>, 32 (2014).","DOI":"10.1186\/1471-230X-14-32"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Craciun EC, Bjorklund G, Tinkov AA, Urbina MA, Skalny AV, Rad F, Dronca E. Evaluation of whole blood zinc and copper levels in children with autism spectrum disorder. Metab. Brain Dis.<\/i>, 31<\/b>, 887\u2013890 (2016).","DOI":"10.1007\/s11011-016-9823-0"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Koumura A, Kakefuda K, Honda A, Ito Y, Tsuruma K, Shimazawa M, Uchida Y, Hozumi I, Satoh M, Inuzuka T, Hara H. Metallothionein-3 deficient mice exhibit abnormalities of psychological behaviors. Neurosci. Lett.<\/i>, 467<\/b>, 11\u201314 (2009).","DOI":"10.1016\/j.neulet.2009.09.051"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis.<\/i>, 3<\/b>, 97\u2013110 (1996).","DOI":"10.1006\/nbdi.1996.0010"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Kariya S, Park GH, Maeno-Hikichi Y, Leykekhman O, Lutz C, Arkovitz MS, Landmesser LT, Monani UR. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet.<\/i>, 17<\/b>, 2552\u20132569 (2008).","DOI":"10.1093\/hmg\/ddn156"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Kong L, Wang X, Choe DW, Polley M, Burnett BG, Bosch-Marce M, Griffin JW, Rich MM, Sumner CJ. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J. Neurosci.<\/i>, 29<\/b>, 842\u2013851 (2009).","DOI":"10.1523\/JNEUROSCI.4434-08.2009"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Le Paslier D, Fr\u00e9zal J, Cohen D, Weissenbach J, Munnich A, Melki J. Identification and characterization of a spinal muscular atrophy-determining gene. Cell<\/i>, 80<\/b>, 155\u2013165 (1995).","DOI":"10.1016\/0092-8674(95)90460-3"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Bowerman M, Becker CG, Yanez-Munoz RJ, Ning K, Wood MJA, Gillingwater TH, Talbot K. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis. Model. Mech.<\/i>, 10<\/b>, 943\u2013954 (2017).","DOI":"10.1242\/dmm.030148"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Kondo H, Miura M, Nakagaki I, Sasaki S, Itokawa Y. Trace element movement and oxidative stress in skeletal muscle atrophied by immobilization. Am. J. Physiol.<\/i>, 262<\/b>, E583\u2013E590 (1992).","DOI":"10.1152\/ajpendo.1992.262.5.E583"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J.<\/i>, 18<\/b>, 39\u201351 (2004).","DOI":"10.1096\/fj.03-0610com"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Urso ML, Chen YW, Scrimgeour AG, Lee PC, Lee KF, Clarkson PM. Alterations in mRNA expression and protein products following spinal cord injury in humans. J. Physiol.<\/i>, 579<\/b>, 877\u2013892 (2007).","DOI":"10.1113\/jphysiol.2006.118042"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Urso ML, Scrimgeour AG, Chen YW, Thompson PD, Clarkson PM. Analysis of human skeletal muscle after 48\u2009h immobilization reveals alterations in mRNA and protein for extracellular matrix components. J. Appl. Physiol.<\/i>, 101<\/b>, 1136\u20131148 (2006).","DOI":"10.1152\/japplphysiol.00180.2006"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) DeRuisseau LR, Recca DM, Mogle JA, Zoccolillo M, DeRuisseau KC. Metallothionein deficiency leads to soleus muscle contractile dysfunction following acute spinal cord injury in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol.<\/i>, 297<\/b>, R1795\u2013R1802 (2009).","DOI":"10.1152\/ajpregu.00263.2009"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Kumar V, Islam A, Hassan MI, Ahmad F. Therapeutic progress in amyotrophic lateral sclerosis\u2014Beginning to learning. Eur. J. Med. Chem.<\/i>, 121<\/b>, 903\u2013917 (2016).","DOI":"10.1016\/j.ejmech.2016.06.017"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Gordon P, Corcia P, Meininger V. New therapy options for amyotrophic lateral sclerosis. Expert Opin. Pharmacother.<\/i>, 14<\/b>, 1907\u20131917 (2013).","DOI":"10.1517\/14656566.2013.819344"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O\u2019Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Bergh R, Hung W-Y, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown RH. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature<\/i>, 362<\/b>, 59\u201362 (1993).","DOI":"10.1038\/362059a0"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Corcia P, Couratier P, Blasco H, Andres CR, Beltran S, Meininger V, Vourc\u2019h P. Genetics of amyotrophic lateral sclerosis. Rev. Neurol.<\/i>, 173<\/b>, 254\u2013262 (2017).","DOI":"10.1016\/j.neurol.2017.03.030"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Puttaparthi K, Gitomer WL, Krishnan U, Son M, Rajendran B, Elliott JL. Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J. Neurosci.<\/i>, 22<\/b>, 8790\u20138796 (2002).","DOI":"10.1523\/JNEUROSCI.22-20-08790.2002"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Tokuda E, Watanabe S, Okawa E, Ono S. Regulation of intracellular copper by induction of endogenous metallothioneins improves the disease course in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics<\/i>, 12<\/b>, 461\u2013476 (2015).","DOI":"10.1007\/s13311-015-0346-x"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Hashimoto K, Hayashi Y, Watabe K, Inuzuka T, Hozumi I. Metallothionein-III prevents neuronal death and prolongs life span in amyotrophic lateral sclerosis model mice. Neuroscience<\/i>, 189<\/b>, 293\u2013298 (2011).","DOI":"10.1016\/j.neuroscience.2011.05.034"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Hozumi I, Yamada M, Uchida Y, Ozawa K, Takahashi H, Inuzuka T. The expression of metallothioneins is diminished in the spinal cords of patients with sporadic ALS. Amyotroph. Lateral Scler.<\/i>, 9<\/b>, 294\u2013298 (2008).","DOI":"10.1080\/17482960801934312"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Blaauwgeers HG, Anwar Chand M, van den Berg FM, Vianney de Jong JM, Troost D. Expression of different metallothionein messenger ribonucleic acids in motor cortex, spinal cord and liver from patients with amyotrophic lateral sclerosis. J. Neurol. Sci.<\/i>, 142<\/b>, 39\u201344 (1996).","DOI":"10.1016\/0022-510X(96)00013-5"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Davis SM, Pennypacker KR. Targeting antioxidant enzyme expression as a therapeutic strategy for ischemic stroke. Neurochem. Int.<\/i>, 107<\/b>, 23\u201332 (2017).","DOI":"10.1016\/j.neuint.2016.12.007"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/7\/41_b17-00856\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T06:23:27Z","timestamp":1571552607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/7\/41_b17-00856\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00856","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}